Combined use of in silico and in vitro splicing assays for interpretation of genomic variants of unknown significance in cardiomyopathies and channelopathies

  • Hervé Crehalet Laboratoire de Cardiogénétique moléculaire, CBPE– Hospices Civils de Lyon, Bron, France.
  • Gilles Millat Laboratoire de Cardiogénétique moléculaire, CBPE– Hospices Civils de Lyon, Bron; EA4612, Université Claude Bernard Lyon 1, Lyon, France.
  • Juliette Albuisson Laboratoire de Génétique Moléculaire, CHU, Hôtel-Dieu, Nantes, France.
  • Véronique Bonnet Laboratoire de Cardiogénétique moléculaire, CBPE– Hospices Civils de Lyon, Bron, France.
  • Isabelle Rouvet Centre de Biotechnologie Cellulaire, CBPE– Hospices Civils de Lyon, Bron, France.
  • Robert Rousson Laboratoire de Cardiogénétique moléculaire, CBPE– Hospices Civils de Lyon, Bron, France.
  • Dominique Bozon | dominique.bozon@chu-lyon.fr Laboratoire de Cardiogénétique moléculaire, CBPE– Hospices Civils de Lyon, Bron, France.

Abstract

The identification of molecular anomalies in patients with inherited arrhythmias or cardiomyopathies is a multi challenge due to: i) the number of genes involved; ii) the number of polymorphisms and the fact that most mutations are private; and iii) the variable degree of penetrance which complicates family segregation study. Consequently, a number of unclassified variants (UV) are found in patients’ DNA and some (outside the canonical GT/AG) may affect splicing. Mutational screening on the most prevalent genes involved in arrythmias syndromes or in cardiomyopathies was performed on a cohort made up of 740 unrelated French index probands. To identify splice variants among the identified UVs, a combination of available in silico and in vitro tools were used since transcript is not available. Using this approach, 10 previously identified UVs were reclassified as disease-causing mutations and, more precisely, as haploinsufficiency mutations rather than dominant-negative mutations. Most of them (7 of 10) were observed in MYBPC3. Our study highlighted the importance of the combined use of in silico and in vitro splicing assays to improve the prediction of the functional impact of identified genetic variants. The primary challenge now, with new sequencing technologies, is to distinguish between background polymorphisms and pathogenic mutations. Since splice site mutations can account for almost 50% of disease-causing mutations, recognizing them from among other variations is essential.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Author Biographies

Hervé Crehalet, Laboratoire de Cardiogénétique moléculaire, CBPE– Hospices Civils de Lyon, Bron
Biochemistry, PhD student
Juliette Albuisson, Laboratoire de Génétique Moléculaire, CHU, Hôtel-Dieu, Nantes
Genetique Moleculaire
Véronique Bonnet, Laboratoire de Cardiogénétique moléculaire, CBPE– Hospices Civils de Lyon, Bron
Biochemistry
Isabelle Rouvet, Centre de Biotechnologie Cellulaire, CBPE– Hospices Civils de Lyon, Bron
Centre de Biotechnologie Cellulaire
Published
2012-06-05
Info
Issue
Section
Original Articles
Keywords:
cardiomyopathies, arrhythmia syndromes, splice mutations, molecular diagnosis.
Statistics
  • Abstract views: 5079

  • PDF: 2450
  • Supplementary: 772
How to Cite
Crehalet, H., Millat, G., Albuisson, J., Bonnet, V., Rouvet, I., Rousson, R., & Bozon, D. (2012). Combined use of in silico and in vitro splicing assays for interpretation of genomic variants of unknown significance in cardiomyopathies and channelopathies. Cardiogenetics, 2(1), e6. https://doi.org/10.4081/cardiogenetics.2012.e6